CandiRes - Understanding how receiving antifungal medications can lead to Candida yeast drug resistance among patients treated in intensive care
Not Applicable
- Conditions
- Antifungal resistance in Candida among ICU patientsInfections and Infestations
- Registration Number
- ISRCTN14165977
- Lead Sponsor
- St George’s University Hospitals NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
1. Age =18 years
2. Currently receiving intravenous antibiotics
3. One or more of the following Candida risk factors:
3.1. Abdominal surgery in the last 4 weeks
3.2. Upper gastrointestinal/mediastinal perforation or surgery in the last 4 weeks
3.3. Liver failure
3.4. Haematological malignancy
3.5. Previous bone marrow or solid organ transplant
3.6. Neutropenia (neutrophils < 0.5*10e9/l)
3.7. Receipt of an immunosuppressive drug (including corticosteroids, chemotherapy, immune-modulators)
3.8. Total parenteral nutrition (TPN)
3.9. Renal replacement therapy
3.10. Extracorporeal membrane oxygenation (ECMO)
4. Suspected invasive candidiasis (added 25/08/2023)
Exclusion Criteria
Expected ICU length of stay <48 h
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method